



Title	Epidemiological alchemy in the AI era comes under close scrutiny—but is it entirely without meaning?
Author(s)	Ide, Kazuki; Nakayama, Takeo
Citation	Journal of Epidemiology. 2025, p. JE20250602
Version Type	AM
URL	<a href="https://hdl.handle.net/11094/103364">https://hdl.handle.net/11094/103364</a>
rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
Note	

*The University of Osaka Institutional Knowledge Archive : OUKA*

<https://ir.library.osaka-u.ac.jp/>

The University of Osaka

*Journal of Epidemiology*

*Letters to the Editor*

**Epidemiological alchemy in the AI era comes under close scrutiny—but is it entirely without meaning?**

Kazuki Ide<sup>1,2\*</sup>, Takeo Nakayama<sup>3</sup>

<sup>1</sup>Division of Scientific Information and Public Policy, Center for Infectious Disease Education and Research (CiDER), The University of Osaka, Osaka, Japan; <sup>2</sup>Research Center on Ethical, Legal and Social Issues, The University of Osaka, Osaka, Japan; <sup>3</sup>Department of Health Informatics, Graduate School of Medicine/School of Public Health, Kyoto University, Kyoto, Japan

\*Address for correspondence. Kazuki Ide, CiDER, The University of Osaka, Osaka, Japan (ide-k@cider.osaka-u.ac.jp, ide.kazuki.2r@kyoto-u.jp; Tel +81-6-6879-4168)

## MAIN TEXT

Epidemiological open data obtained from the National Health and Nutrition Examination Survey (NHANES), conducted in the United States, have provided valuable opportunities for exploratory research [1]. What once embodied the public good may now, in the artificial intelligence (AI) era, be revealing the seductive sheen of a “forbidden fruit.”

Suchak T et al. reported an increase in formulaic research articles using this AI-ready dataset (four articles per year from 2014 to 2021, but 190 in 2024 alone as of October 9), among which a considerable proportion were of questionable quality [2]. They suggested that this increase was partly driven by AI-assisted workflows and paper mills.

After this problematic trend was reported in *Science*, two major publishers—PLOS and Frontiers—announced that they would no longer consider studies based solely on this dataset without additional research [3]. This means that authors are now required to include experiments demonstrating robustness or to incorporate additional data from their own institutions to show the unique value of the study. The Editor-in-Chief of PLoS One stated that “*the rejection rate for such papers has increased from 40% to 94%,”* although it remains difficult to judge whether this change is desirable. A

94% rejection rate seems high. We argue that frequent reuse of a dataset tends to signal FAIR (Findable, Accessible, Interoperable, Reusable)-aligned quality. In this context, Dr Mons has underscored the importance of “Fully AI-Ready” data [4]. We should therefore remain mindful of the risk of becoming unduly restrictive or overly exclusionary toward exploratory, early-stage work. Not limited to NHANES, the journal *Globalization and Health* has also discussed issues in Global Burden of Disease (GBD) studies, which may stem from comparable problems [5].

In Japan, collaborative studies such as the Japan COVID-19 and Society Internet Survey (JACSIS) and the Japan Society and New Tobacco Internet Survey (JASTIS) have conducted multiple waves of data collection [6, 7]. These groups regularly invite collaborators to use their data, although the datasets are not openly available. Their controlled-access framework represents one possible solution for preventing inappropriate use of data, provided it safeguards a minimum level of quality while remaining open to diverse research. A similar approach is used by the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study, which provides open calls for research proposals to researchers awarded Grants-in-Aid for Scientific Research (KAKENHI) [8]. The initiative is also supported by the Platform of Supporting Cohort Study and Biospecimen Analysis (CoBiA), which includes additional resources [9].

Another approach is to require authors to post a preprint upon submission, as previously implemented by *eLife*. Such a policy may function as a deterrent against inappropriate use of data and the submission of low-quality manuscripts, since authors' names remain publicly associated with their work even if it is ultimately rejected. That said, its impact might be limited, given that the generalist server hosted on *OSF Preprints* released a blog post on October 16, 2025, announcing its decision to indefinitely suspend operations, citing concerns over the rising volumes of AI-generated content and paper-mill activities as one reason for the suspension [10].

Furthermore, discerning whether insufficient quality stems from malicious intent or a mere lack of rigor remains a challenge. Care must be taken not to conflate the level of expertise or methodological rigor with malicious intent, as such assumptions risk stifling emerging research and discouraging ambitious researchers. Importantly, health-related data and the findings derived from them may influence both individual and population-level behavior.

We are living in an age of openness, with this trend being advanced at both national and international levels [11]. It may be time for us not merely to advance openness, but to proactively rethink its meaning and form—an invitation posed by the very phenomena we are now witnessing.

**Ethical Approval**

This commentary is based exclusively on information from public sources that contain no personal information; therefore, ethical approval was not required.

**Data Availability Statement**

All data are incorporated into the article.

**Acknowledgements**

This work was conducted as part of “The Nippon Foundation – The University of Osaka Project for Infectious Disease Prevention” and was supported by a Grant-in-Aid for Early-Career Scientists from the Japan Society for the Promotion of Science (23K12845 to KI).

**Conflict of Interest**

KI received consulting fees from Mimir, Inc.; payment or honoraria for lectures, manuscript writing, or educational events from Bon Bon Inc., Eisai Co., Ltd., Japan Medical and Scientific Communicators Association, Research University Consortium, The Foundation for Dietary Scientific Research, outside the submitted work. He is also a member of the Editorial Policy Advisory Group of the Directory of Open Access Journals (DOAJ). TN received grants or contracts from I&H Co., Ltd., Cocokarafine Group Co., Ltd., Konica Minolta, Inc., NTT DATA, Inc., Takeda Pharmaceutical Co.,

Ltd.; consulting fees from Ohtsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Johnson & Johnson K.K., AstraZeneca plc.; payment or honoraria for lectures, manuscript writing, or educational events from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH., Eli Lilly Japan K.K., Maruho Co., Ltd., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Allergan Japan K.K., Novo Nordisk Pharma Ltd., TOA EIYO Ltd., AbbVie Inc., ONO PHARMACEUTICAL CO., LTD., GSK plc, Alexion Pharmaceuticals, Inc., Canon Medical Systems Co., Kowa Company, Ltd., Araya Inc., Merck & Co., Amicus Therapeutics, Inc., CSL Behring K.K., Amgen Inc., Sanofi S.A.; stock options from Bon Bon Inc., outside the submitted work.

The authors thank Dr. Masanori Oikawa for insightful discussions and acknowledge the use of ChatGPT (OpenAI, San Francisco, CA, USA) for language-editing assistance.

## References

1. Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Survey (NHANES).  
<https://www.cdc.gov/nchs/nhanes/about/index.html>; Accessed 11.05.2025.
2. Suchak T, Aliu AE, Harrison C et al. Explosion of formulaic research articles, including inappropriate study designs and false discoveries, based on the NHANES US national health database. *PLoS Biol.* 2025;23(5): e3003152. doi: 10.1371/journal.pbio.3003152
3. O'Grady C. Journals and publishers crack down on research from open health data sets. *Science*. 2025, *in press*. doi: 10.1126/science.z6eukgo
4. Farewell address Barend Mons. <https://www.gofair.foundation/fairwell>; Accessed 11.11.2025.
5. Globalization and Health. Aims and Scope.  
<https://globalizationandhealth.biomedcentral.com/about>; Accessed 11.11.2025.
6. Tabuchi T, Shinozaki T, Kunugita N et al. Study profile: The Japan "Society and New Tobacco" Internet Survey (JASTIS): A longitudinal internet cohort study of heat-not-burn tobacco products, electronic cigarettes, and conventional tobacco products in Japan. *J Epidemiol.* 2019;29:444-50. doi: 10.2188/jea.JE20180116



7. The Japan COVID-19 and Society Internet Survey (JACSIS Study). <https://jacsis-study.jp/index.html>; Accessed 11.05.2025.
8. J-MICC STUDY. <https://jmicc.com/>; Accessed 11.11.2025. [In Japanese]
9. Platform of Supporting Cohort Study and Biospecimen Analysis. <https://square.umin.ac.jp/cohort/english/index.html>; Accessed 11.11.2025.
10. Center for Open Science (COS). OSF update on the future of OSF Preprints. <https://www.cos.io/blog/update-on-future-of-osf-preprints>; Accessed 10.29.2025.
11. Ide K. Japan can embrace open science — but flexible approaches are key. *Nature*. 2024;629:286. doi: 10.1038/d41586-024-01340-w